Form 4: Cidara CMO Sells Shares for Tax Obligations

Cidara Therapeutics' Chief Medical Officer, Nicole Negar Davarpanah, sold 474 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Chief Medical Officer Nicole Negar Davarpanah reported a transaction involving Cidara Therapeutics, Inc. common stock.
• 474 shares of common stock were sold on September 11, 2025.
• The sale was executed at a weighted average price of $62.8627 per share, with individual transaction prices ranging from $62.86 to $63.50.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units (RSUs), and it was not a discretionary transaction.
• Following this reported transaction, Nicole Negar Davarpanah beneficially owns 31,418 shares of common stock.
• The reported beneficial ownership includes 200 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2025.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax obligations related to RSU vesting, which is a neutral event for the company's operational performance but reflects executive compensation realization.

Positives

• Vesting of Restricted Stock Units (RSUs) for the Chief Medical Officer indicates compensation realization.
• Acquisition of 200 shares through the Employee Stock Purchase Plan on May 20, 2025, demonstrates continued employee investment in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The transaction represents a minor, non-discretionary sale by an executive, which is generally viewed as neutral and does not indicate a change in company fundamentals.
• Employees: The filing demonstrates the company's RSU compensation structure and the standard process for handling tax obligations upon vesting.

Key Dates

Recommendation

The reported transaction is a non-discretionary 'sell to cover' by a Chief Medical Officer to satisfy tax obligations from RSU vesting. This is a routine event and does not reflect a change in the executive's view of the company's prospects or fundamental performance. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Cidara Therapeutics, CDTX, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Chief Medical Officer, Nicole Negar Davarpanah, Beneficial Ownership